syndecan-1和-2表达形式的变化可以预测前列腺癌生化复发

前列腺癌的临床特点不能准确确定患者是否会发生生化复发，因而不适合作为预后和复发的指标。需要新的分子标记物对患者进行适当的术前风险分层。本研究旨在评估syndecan-1和-2的表达改变是否可以预测临床局限性前列腺癌患者行前列腺根治术后的生化复发。取60份局限性前列腺癌患者的石蜡包埋组织标本，采用免疫组化染色检测syndecan-1和-2的表达。取10份良性前列腺增生患者的样本作为非恶性对照。利用半定量分析，对其进行染色评估。为探讨预后效果，用Kaplan—Meier生存曲线进行分析，并进行log—rank检验。在良性前列腺样本中，syndecan-1在基底层上皮细胞中有表达，在上皮分泌细胞的基侧膜上也有表达；syndecan-2则主要但挞底层上皮细胞中表达。前列腺癌样本中，两种syndecan的表达模式都转变成定位在颗粒状细胞质上。生存分析显示，在游离前列腺特异性抗原（fPSA）复发存活曲线中，正常和改变的syndecan-1和-2的表达存在显著差异（P〈0．05）。这些数据表明，syndecan—1和-2可以作为临床局灶性前列腺癌患者预后的标记物，从而改进前列腺特异性抗原（PSA）评估复发风险，增加风险分层。

Altered expression patterns of syndecan-1 and ,2 predicl biochemical recurrence in prostate cancer

The clinical features of prostate cancer do not provide an accurate determination of patients undergoing biochemical relapse and are therefore not suitable as indicators of prognosis for recurrence. New molecular markers are needed for proper pre-treatment risk stratification of patients. Our aim was to assess the value of altered expression of syndecan-1 and -2 as a marker for predicting biochemical relapse in patients with clinically localized prostate cancer treated by radical prostatectomy. The expression of syndecan-1 and -2 was examined by immunohistochemical staining in a series of 60 paraffin-embedded tissue samples from patients with localized prostate cancer. Ten specimens from patients with benign prostatic hyperplasia were used as non-malignant controls. Semiquantitative analysis was performed to evaluate the staining patterns. To investigate the prognostic value, Kaplan-Meier survival curves were performed and compared by a log-rank test. In benign samples, syndecan-1 was expressed in basal and secretory epithelial cells with basolateral membrane Iocalisation, whereas syndecan-2 was expressed preferentially in basal cells. In prostate cancer samples, the expression patterns of both syndecans shifted to granular-cytoplasmic Iocalisation. Survival analysis showed a significant difference （P〈0.05） between normal and altered expression of syndecan-1 and -2 in free prostate-specific antigen recurrence survival curves. These data suggest that the expression of syndecan-1 and -2 can be used as a prognostic marker for patients with clinically localized orostate cancer, improving the larostate-specific antigen recurrence risk stratification.